Press Releases

 Filter by Provider

JERSEY CITY, NJ / ACCESS Newswire / May 31, 2025 / Are you in search of the best crypto casinos available in the industry? Then, you are in the right spot! We have come up with a list of the top five best gambling sites with the help of our experts. The details about the crypto gambling sites are given below for your reference.

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of its Fuses program. This initiative will harness Tempus’ proprietary dataset to generate valuable insights for both patient care and research, combining the power of its data and machine learning capabilities to develop an AI enabled-diagnostic platform offering physicians the largest suite of algorithmic tests designed to make precision medicine a reality.

Discover if NetherexPro's AI-powered trading robot is legit. Read our in-depth 2025 review on its accuracy, performance, security, and real user results!

Discover if Immediate Luminary AI trading robot is safe and effective. Read our in-depth 2025 review to learn features, performance, security, real feedback.

SINGAPORE, SG / ACCESS Newswire / May 31, 2025 / PowerTrade, the market-leading altcoin-options exchange, today announces that its ultra-short-dated 10-minute and 1-hour option contracts are now live for BTC on both the PowerTrade CEX and PowerDEX with zero fees. To make them accessible to every trader, the company is simultaneously rolling out PowerTrade Lite - a streamlined interface where a single click on the chart automatically selects the highest-ROI contract, no option chain or Greeks required.

Comprehensive 2025 Guide Explores Ingredients, Benefits, Real User Results, and Pricing for This 2,000-Year-Old African-Inspired Vitality Formula

PUNE, INDIA / ACCESS Newswire / May 31, 2025 / -Investing in the stock market can be rewarding, but smart investing starts with knowing how to read financial statements. These documents reveal a company's financial health and are essential for evaluating whether a stock is worth your money.

GO INVEST LLC, a global comprehensive financial technology group, is making waves with the completion of the full acquisition of the leading quantitative trading platform Firefly Star. These two parties merged into Flicker Algo to create a new highland for global intelligent trading.

ispace, inc. (ispace) (TOKYO: 9348), a global lunar exploration company, announced today that the RESILIENCE lunar lander has successfully completed all orbital maneuvers while in lunar orbit and is now being prepared for its landing attempt on June 6, 2025.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147) involving over 2,000 patients with stage III colon cancer with median follow-up of 6.1 years were presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Phase III INAVO120 study. These data showed ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, reduced the risk of death by more than 30% compared with palbociclib and fulvestrant alone. This represents a statistically significant and clinically meaningful improvement in overall survival for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine-resistant, locally advanced or metastatic breast cancer. The results are being presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in the New England Journal of Medicine (NEJM).

A Comprehensive Look at HepatoBurn: Does This Dual-Action Liver Detox Supplement Truly Tackle Belly Fat, Energy Slumps, and Metabolism Struggles-Or Are the Official Claims Too Good to Be True?

Burlington Security Pros launches homesecurityburlington.com to help residents of Burlington, MA, and the surrounding areas connect with trusted local home security companies.

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001)

NEW HAVEN, Conn. and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer (MBC) whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These data, which were highlighted in the American Society of Clinical Oncology (ASCO®) press briefing and selected for Best of ASCO, will be presented today in a late-breaking oral presentation (Abstract LBA1000) and have been simultaneously published in the New England Journal of Medicine.

ELKHORN, NE / ACCESS Newswire / May 31, 2025 / United Republic Bank, a trusted community-focused financial institution, has officially launched its new, modern website, designed and developed by OMNICOMMANDER in response to a third party's recent sunset of its website hosting platform. The new site features a sleek, mobile-responsive design, full ADA accessibility, and a user experience tailored to both personal and business clients.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy) reduced the risk of disease progression or death by 35% (HR=0.65, p<0.001) versus KEYTRUDA plus chemotherapy for the first-line treatment of patients with PD-L1+ (Combined Positive Score [CPS] ≥10) inoperable (unresectable) locally advanced or metastatic triple-negative breast cancer (TNBC), as determined by an FDA-approved test. KEYTRUDA, when given in combination with Gilead’s TROP2 antibody-drug conjugate (ADC) Trodelvy, resulted in a median progression-free survival (PFS) of 11.2 months versus 7.8 months when KEYTRUDA was given in combination with chemotherapy. These data from the pivotal Phase 3 ASCENT-04/KEYNOTE-D19 study will be presented today as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA109) and were selected for the official ASCO Press Program.

High school students who quickly answered tough questions posed to state-championship teams at the Council for Economic Education’s National Economics Challenge (NEC) finals may not change the world today.

Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and simultaneously published in the Journal of Clinical Oncology.

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression or death by 35% (HR: 0.65) versus standard of care Keytruda plus chemotherapy in first-line treatment for patients with PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). Trodelvy when given in combination with Keytruda resulted in a median progression-free survival (PFS) of 11.2 months vs 7.8 months when Keytruda was given in combination with chemotherapy. These data from the pivotal Phase 3 ASCENT-04/KEYNOTE-D19 study will be presented today as a late-breaking oral presentation at the 2025 ASCO Annual Congress (Abstract #LBA109).

Positive results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to ramucirumab plus paclitaxel in patients with second-line HER2 positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Results will be presented today as a late-breaking oral presentation (LBA #4002) at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting and simultaneously published in The New England Journal of Medicine.

Mythic Therapeutics, a clinical-stage biotechnology company developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today presented updated data from its Phase 1 KisMET-01 study evaluating its investigational cMET-targeting ADC candidate, MYTX-011, in patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC), in a poster at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. MYTX-011 is a novel ADC engineered with pH-dependent binding to more precisely deliver anti-tumor payload across a range of cMET expression levels, with the goal of reducing toxicity and expanding the number of patients who can benefit from ADC therapy.

Stafford, Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the presentation of expanded data from the ongoing Phase 1b clinical trial evaluating IMA203 PRAME cell therapy in heavily pretreated patients with metastatic melanoma. The longer follow-up of patients demonstrates a consistent and favorable tolerability profile as well as durable responses with a confirmed ORR of 56%. In addition, the Company provided details from a Trial in Progress poster on SUPRAME, the ongoing Phase 3 clinical trial evaluating IMA203 in patients with unresectable or metastatic cutaneous melanoma who have received prior treatment with a checkpoint inhibitor.

PARIS, France, 31 May 2025 – Late-breaking (LBA4175) post-hoc analysis data from the Phase III NAPOLI 3 study were presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. These results found a median overall survival (mOS) of 19.5 months among long-term survivors (n=15) with metastatic pancreatic adenocarcinoma (mPDAC) treated with the Onivyde® (irinotecan liposome injection) plus oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) regimen as a first-line treatment (n=120), with younger age at diagnosis, and certain tumor and metastasis locations associated with long-term survivorship.2

Students win $3,000 in Shark Tank-style pitch competition and advance to national finals

26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases

Ocasta has launched an innovative platform to enhance the performance of frontline teams and help companies excel in their fields.

Ohio Functional Rehab leverages digital health tools and telemedicine to enhance multidisciplinary care, improving recovery outcomes for car accident victims across Ohio.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - May 31, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Red Cat Holdings, Inc. (“Red Cat” or the “Company”) (NASDAQ: RCAT) on behalf of investors that purchased or otherwise acquired Red Cat securities between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”).

Shout Softly Shirts unveils a new apparel collection blending fine art inspiration with a mission for empathy and activism

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK, NY - May 31, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Ibotta, Inc. (“Ibotta” or the “Company”) (NYSE: IBTA) on behalf of Ibotta investors.

Investment Platform’s Users’ Accounts Have Been Frozen Since February

ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data (MMD) solutions for healthcare and life sciences, today announced the integration of the American Society of Clinical Oncology® (ASCO®) Guidelines through the CARAai platform for its Precision Suite and CancerLinQ® SmartLinQ solutions™. Now, the power of the Precision Suite’s low-latency and high-recency data can be used by biopharma researchers to assess Guideline-concordant care and outcomes at any point in time or reviewing changes over time. Members of the CancerLinQ® network using SmartLinQ solutions will now have ASCO Guideline-concordant recommendations for their individual patients as an augmentation of their assessment of treatment options. This published information will be integrated with other SmartLinQ features that can help oncologists consider a complete set of treatment options for optimized patient outcomes.

Kuala Lumpur, Malaysia, 31st May 2025 – Halal Holidays today announced the official launch of its dedicated Muslim-friendly travel platform, HalalHolidays.asia, addressing the rapidly expanding halal tourism sector projected to reach US$225 billion by 2028. The new platform offers fully halal-certified travel packages, accommodations, and seamless booking experiences specifically designed for faith-conscious travellers.

Halal Holidays Officially Launches HalalHolidaysasia to Meet the Soaring Demand for Muslim Friendly Travel Across Asia

ATLANTA, GA / ACCESS Newswire / May 31, 2025 / Nfinity Athletic, a top manufacturer of women's cheerleading gear, has the ultimate line of cheer gear, including cheerleading shoes, backpacks, and uniforms made from high-tech materials and engineered for athletes. The collection focuses on performance, durability, and protection, which cater to the dynamic demands of cheerleaders at every skill level.

Narvon, PA – Zerbe Retirement Community, a family-founded and faith-based senior living campus, continues to provide compassionate care and vibrant retirement living in the heart of Lancaster County. Known for its commitment to dignity, respect, and personalized service, Zerbe Retirement Community offers a welcoming environment where seniors can thrive with peace of mind and purpose.

Beauty Lives Travel Salon LLC, an established hair studio in Atlanta, GA, excels in providing affordable, professional services such as hair coloring, braiding, dreadlock extensions, and styling for special events. With a focus on creativity and client satisfaction, the salon remains a dynamic and trusted choice for Atlanta residents.

Lenora’s Healthy Hair Clinic and Spa, a new beauty salon in Cleveland Heights, OH, has launched with a focus on specialized hair care services, including therapy, alopecia solutions, and hair replacement. Committed to healthy, natural hair, the salon offers personalized, expert care, positioning itself as a premier destination for Cleveland Heights residents.

Infinity Beauty Spa Tukwila, an established beauty salon in Tukwila, WA, continues to excel in providing specialized services such as microblading, eyelash extensions, and lip blush tattoos. Committed to enhancing natural beauty, the salon offers expert care and personalized solutions, solidifying its role as a trusted destination for Tukwila residents.

Elvias Salon, an established beauty salon in Garner, NC, continues to provide exceptional services, including hair coloring, styling, make-up, manicures, pedicures, and barber services. With a focus on affordability and quality, the salon remains a beloved destination for Garner residents seeking personalized beauty care.

JV Micropigmentation & Beauty, an established beauty salon in Rockaway, NJ, excels in providing permanent makeup services such as microblading, eyebrow permanent makeup, lip micropigmentation, and waxing. With a focus on precision and client satisfaction, the salon remains a trusted destination for Rockaway residents seeking lasting beauty solutions.

New data shows that SoHo's 7.3 million square feet of office space is experiencing renewed interest from tenants seeking boutique, loft-style environments. Mitch Waldman of Cogent Realty Advisors highlights new availabilities and market trends in his latest SoHo leasing guide for commercial tenants.

AI won’t take your job, but someone using it might. This new university helps you stay ahead.

San Jose, California, 31st May 2025, AgentikDEX, a groundbreaking decentralized application that transforms complex trading algorithms into accessible, autonomous AI agents, today announced its official launch on Believe.app. The platform represents a paradigm shift in decentralized finance, enabling users to deploy sophisticated trading strategies across multiple blockchains without requiring technical expertise.

Calgary, AB - May 31, 2025 - Solos Energy, a Canadian-owned solar company founded in 2021, is excited to announce the launch of its Southern Alberta service region, now serving Calgary, Airdrie, Cochrane, Okotoks, Chestermere, and surrounding communities.

Anchorage, AK – As temperatures in Alaska swing between extremes, the demand for reliable heating and plumbing services is more important than ever. Stepping in to meet this need is 907 Heating and Plumbing, a trusted local business committed to delivering high-quality, dependable services to residential and commercial clients across Anchorage.